Jaap Jan Boelens, MD, PhD

Memorial Sloan Kettering pediatric hematologic oncologist Jaap-Jan Boelens

Dr. Jaap Jan Boelens is the director of the IDMS lab. Dr. Boelens, who is also the Chief of the Pediatric Transplantation and Cellular Therapy Program,  came to Memorial Sloan Kettering from UMC Utrecht and the Princess Maxima Center for Pediatric Oncology, where he worked on developing the largest umbilical cord blood transplant program in Europe. His lab in Utrecht also developed and validated multiple PK and PD models for drugs given in the conditioning regimen and they have related drug exposures to immune reconstitution and clinical outcomes. His mission is by individualizing the conditioning regimens to create to most favorable immune milieu for disease control (efficacy) and infection / GvHD control (safety) after transplantation and cellular therapy. At MSKCC, Dr. Boelens continues to find new ways to advance cord blood and other cellular therapies, as well as to create predictive models for response to treatments.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Jaap Jan Boelens discloses the following relationships and financial interests:

  • Roche
    Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures